Post Market Clinical Follow-up of CRT-DX Therapy With Lumax 640/740 HF-T

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

18 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-08-31

Study Completion Date

2014-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is designed to collect data of the performance and confirm the safety of the DX (Diagnostic eXtension) functionality in the Lumax 640/470 HF-T in patients with permanent atrial fibrillation and CRT-D indication according to current ESC guidelines. The DX functionality is a feature, which can be activated in the Lumax 640/740 HF-T when connected to the LinoxSMART S DX right ventricular lead. The combination of these devices enable atrial sensing via a sensing dipole in the ventricular lead and therefore reduces the number of implanted leads without sacrificing atrial information. Atrial pacing can not be provided but is not needed in patients with permanent atrial fibrillation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Management and Detection of Atrial Tachyarrhythmias in Patients Implanted With BIOTRONIK DX Systems

NCT01774357

Atrial Fibrillation Tachycardia ICD Therapy +2 more

COMPLETED

Safety and Performance Aspects of CRT-DX System in Patients With Sinus Rhythm

NCT03839121

Heart Failure Cardiac Resynchronization Therapy

COMPLETED

Lumax DX / Linox DX Evaluation

NCT01486836

Cardiac Disease

COMPLETED

Interventricular Delay of Lumax HF-T for Heart Failure

NCT00508391

Congestive Heart Failure

COMPLETED PHASE2

Observation of Clinical Routine Care for Heart Failure Patients Implanted With BIOTRONIK CRT Devices

NCT03366545

Heart Failure

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* CRT-D indication according to current ESC guidelines (NYHA III/IV; QRS≥120ms; LVEF≤35%; Expected survival ≥ 1 year; need for pacing because of slow ventricular rate or pacemaker dependency as a result of AV nodal ablation or ventricular rate ≤60bpm at rest and ≤90bpm on exercise)
* Permanent atrial fibrillation
* Patients planned to be implanted with BIOTRONIK Lumax 640/740 HF-T
* Patients planned to be implanted with BIOTRONIK LinoxSmart S DX right ventricular lead (or successors)
* Patient eligible for programming of DX functionality according to the physicians' decision
* Patient is willing and able to comply with the CIP and provided written informed consent
* Patient accepts Home Monitoring® concept and has sufficient GSM/GPRS coverage

Exclusion Criteria

* Patients with any contraindication to CRT-D therapy
* Patients listed for heart transplantation
* Life expectancy less than 12 months
* Pregnant or breast-feeding women
* Patients under the age of 18
* Patients with limited contractual capability
* Participation in any other clinical study

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No